Physician

Muhammad Ahsan Baig, MD

According to 2025 Medicare claims, Muhammad Baig, MD (NPI: 1730355256) practices nephrology in the Erie, PA market, with the plurality of this provider's patient population coming from Erie, PA. This provider's primary affiliated billing organization is ASSOCIATES IN NEPHROLOGY PC (NPI: 1568419448; TIN: 251356745) and primary practice location at 16544-0002.

Baig's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 416 traditional Medicare patients, billed 2,071 HCPCS/CPT codes, and received $136,582 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 2,303 prescription claims across 389 beneficiaries totaling $590,435 in drug costs, led by Jynarque (Tolvaptan). DME data shows 187 claims. Open Payments data shows 4 records totaling $186. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $284,736 to $590,435. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $0 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	603	2,928	$207,315
2016	570	2,647	$198,443
2017	575	2,564	$184,362
2018	522	3,385	$193,907
2019	522	2,620	$202,086
2020	558	3,126	$198,237
2021	501	2,797	$171,790
2022	455	2,141	$142,923
2023	475	2,427	$148,970
2024	416	2,071	$136,582

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	289	2,511	$284,736
2016	292	2,392	$312,968
2017	276	2,068	$279,604
2018	309	2,077	$227,340
2019	333	2,033	$198,994
2020	328	2,049	$201,624
2021	340	2,228	$202,031
2022	355	2,192	$166,383
2023	397	2,429	$189,558
2024	389	2,303	$590,435

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	43	$2,939
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	22	$706
2020	N/R	58	$1,694
2021	N/R	133	$2,991
2022	N/R	140	$2,937
2023	N/R	134	$2,583
2024	N/R	187	$2,943

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	37	47	$287
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	101	108	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	139	199	$70
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	161	592	$64
90935	Hemodialysis procedure with physician evaluation	50	129	$57

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jynarque	Tolvaptan	24	672	$461,401
Procrit	Epoetin Alfa	12	526	$9,727
Sevelamer Carbonate	Sevelamer Carbonate	39	1,530	$7,045
Bumetanide	Bumetanide	178	10,254	$6,604
Cinacalcet Hcl	Cinacalcet Hcl	29	1,392	$5,623

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	65	$1,178
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	46	$828
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	47	$552
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	29	$386

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	4	$186	Boston Scientific Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad Ahsan Baig, MD?

Tedicare shows public-source Medicare data for Muhammad Ahsan Baig, MD (NPI 1730355256), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad Ahsan Baig, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Muhammad Ahsan Baig, MD?

Muhammad Ahsan Baig, MD is linked to ASSOCIATES IN NEPHROLOGY PC (billing NPI 1568419448) in the available physician profile data.

Does Muhammad Ahsan Baig, MD have Open Payments data?

Muhammad Ahsan Baig, MD has 4 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.